British Columbia’s Opioid Substitution Treatment (formerly Methadone Maintenance Therapy1 ) made a switch in formulation from generic methadone to a proprietary medication called Methadose™ (BC Ministry of Health, 2013) effective February 1 of 2014. The switch to Methadose™ in British Columbia (BC) offers an opportunity to examine the literature about methadone, MMT, and opioids and trace the evolution of policy and practice that inform this substitution therapy. A metanarrative review of the literature demonstrates the evolving perspective on MMT and offers insights to how a society views substance use, as well as future medication changes that affect a particular patient population, especially when that population is comprised of individuals who face structural inequities in mainstream Canadian society
Copyright is held by the author(s).
Member of collection